EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 3.0

Analysis of Plasma Circulating Tumor DNA in Borderline Resectable Pancreatic Cancer Treated with Neoadjuvant Modified FOLFIRINOX: Clinical Relevance of DNA Damage Repair Gene Alteration Detection

Dong-Hoon Lim, Hyunseok Yoon, Kyu-Pyo Kim, Baek-Yeol Ryoo, Sang Soo Lee, Do Hyun Park, Tae Jun Song, Dae Wook Hwang, Jae Hoon Lee, Ki Byung Song, Song Cheol Kim, Seung-Mo Hong und 2 weitere

Cancer Research and Treatment · 2023

DOI: 10.4143/crt.2023.452 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Research and Treatment, 2023. Verfasst von Dong-Hoon Lim und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea. Hauptthemen laut MEDLINE: Pancreatic Neoplasms, Circulating Tumor DNA. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0). Gefördert von: Asan Institute for Life Sciences, Asan Medical Center, Servier, Bayer.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

There are no reliable biomarkers to guide treatment for patients with borderline resectable pancreatic cancer (BRPC) in the neoadjuvant setting. We used plasma circulating tumor DNA (ctDNA) sequencing to search biomarkers for patients with BRPC receiving neoadjuvant mFOLFIRINOX in our phase 2 clinical trial (NCT02749136).Materials and Methods Among the 44 patients enrolled in the trial, patients with plasma ctDNA sequencing at baseline or post-operation were included in this analysis. Plasma cell-free DNA isolation and sequencing were performed using the Guardant 360 assay. Detection of genomic alterations, including DNA damage repair (DDR) genes, were examined for correlations with survival.

Results

Among the 44 patients, 28 patients had ctDNA sequencing data qualified for the analysis and were included in this study. Among the 25 patients with baseline plasma ctDNA data, 10 patients (40%) had alterations of DDR genes detected at baseline, inclu-ding ATM, BRCA1, BRCA2 and MLH1, and showed significantly better progression-free survival than those without such DDR gene alterations detected (median, 26.6 vs. 13.5 months; log-rank p=0.004). Patients with somatic KRAS mutations detected at baseline (n=6) had significantly worse overall survival (median, 8.5 months vs. not applicable; log-rank p=0.003) than those without. Among 13 patients with post-operative plasma ctDNA data, eight patients (61.5%) had detectable somatic alterations.

Conclusion

Detection of DDR gene mutations from plasma ctDNA at baseline was associated with better survival outcomes of pati-ents with borderline resectable pancreatic ductal adenocarcinoma treated with neoadjuvant mFOLFIRINOX and may be a prognostic biomarker.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Pancreatic NeoplasmsCirculating Tumor DNAHumansAntineoplastic Combined Chemotherapy ProtocolsNeoadjuvant TherapyClinical RelevanceDNA DamageBiomarkersBiomarkers, TumorLeucovorinFluorouracilIrinotecanOxaliplatin

Stichwörter der Autor:innen

Borderline resectable pancreatic cancerCirculating-tumor DNADNA damage repairNeoadjuvantPlatinum sensitivitymFOLFIRINOX

Substanzen

Circulating Tumor DNABiomarkersBiomarkers, TumorfolfirinoxLeucovorinFluorouracilIrinotecanOxaliplatin

Autor:innen und Institutionen

  • Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
  • Department of Gastroenterology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
  • Department of Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
  • Department of Pathology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.

Förderung

  • Asan Institute for Life Sciences, Asan Medical Center
  • Servier
  • Bayer
  • AstraZeneca
  • Ono Pharmaceuticals
  • Celgene
  • Ipsen
  • Boryung Pharmaceuticals

Zitieren

APA

Lim, D. H., Yoon, H., Kim, K. P., Ryoo, B. Y., Lee, S. S., Park, D. H., Song, T. J., Hwang, D. W., Lee, J. H., Song, K. B., Kim, S. C., Hong, S. M., Hyung, J., & Yoo, C. (2023). Analysis of Plasma Circulating Tumor DNA in Borderline Resectable Pancreatic Cancer Treated with Neoadjuvant Modified FOLFIRINOX: Clinical Relevance of DNA Damage Repair Gene Alteration Detection. Cancer Research and Treatment. https://doi.org/10.4143/crt.2023.452

Vancouver

Lim DH, Yoon H, Kim KP, Ryoo BY, Lee SS, Park DH, et al. Analysis of Plasma Circulating Tumor DNA in Borderline Resectable Pancreatic Cancer Treated with Neoadjuvant Modified FOLFIRINOX: Clinical Relevance of DNA Damage Repair Gene Alteration Detection. Cancer Research and Treatment. 2023. doi:10.4143/crt.2023.452

BibTeX
@article{Lim2023,
  author = {Lim, Dong-Hoon and Yoon, Hyunseok and Kim, Kyu-Pyo and Ryoo, Baek-Yeol and Lee, Sang Soo and Park, Do Hyun and Song, Tae Jun and Hwang, Dae Wook and Lee, Jae Hoon and Song, Ki Byung and Kim, Song Cheol and Hong, Seung-Mo and Hyung, Jaewon and Yoo, Changhoon},
  title = {Analysis of Plasma Circulating Tumor DNA in Borderline Resectable Pancreatic Cancer Treated with Neoadjuvant Modified FOLFIRINOX: Clinical Relevance of DNA Damage Repair Gene Alteration Detection},
  journal = {Cancer Research and Treatment},
  year = {2023},
  doi = {10.4143/crt.2023.452}
}
Kostenlos starten →